U.S. Markets open in 7 hrs 23 mins
  • S&P Futures

    3,262.25
    -12.75 (-0.39%)
     
  • Dow Futures

    26,952.00
    -103.00 (-0.38%)
     
  • Nasdaq Futures

    10,929.25
    -59.75 (-0.54%)
     
  • Russell 2000 Futures

    1,475.80
    -7.00 (-0.47%)
     
  • Crude Oil

    39.22
    -0.09 (-0.23%)
     
  • Gold

    1,915.70
    +5.10 (+0.27%)
     
  • Silver

    24.58
    +0.19 (+0.77%)
     
  • EUR/USD

    1.1761
    -0.0012 (-0.1058%)
     
  • 10-Yr Bond

    0.6710
    0.0000 (0.00%)
     
  • Vix

    27.78
    +1.95 (+7.55%)
     
  • GBP/USD

    1.2800
    -0.0017 (-0.1318%)
     
  • BTC-USD

    10,494.38
    +56.66 (+0.54%)
     
  • CMC Crypto 200

    223.01
    -12.57 (-5.34%)
     
  • FTSE 100

    5,804.29
    -202.76 (-3.38%)
     
  • Nikkei 225

    23,360.30
    +40.90 (+0.18%)
     

Kite Pharma Leads IBB’s Mid-Caps on Its Zuma-1 Phase 1 Results

Peter Neil

IBB Falls as Biotechs Bear the Weight of Global Pressures

(Continued from Prior Part)

IBB’s mid-caps under pressure

The mid-cap (middle capitalization) stocks of the iShares Nasdaq Biotechnology ETF (IBB) fell as much as 2.6% on December 7, 2015, underperforming the SPDR S&P 500 ETF (SPY) and the IBB, which returned -0.6% and -2.3%, respectively.

Among the 30 mid-cap stocks that IBB holds in its portfolio, 27 ended up in the red, while three gave positive returns on the day. IBB’s mid-cap stocks account for ~19.1% of its portfolio. Top mid-cap performers included Kite Pharma (KITE) and Qiagen (QGEN), which returned 1.2% and 0.4%, respectively. Bottom mid-cap performers included Alnylam Pharmaceuticals (ALNY) and Novavax (NVAX), which returned -10.3% and -7.5%, respectively.

The above graph reflects the performances of IBB’s mid-caps, IBB, and SPY. Since the beginning of December 2015, IBB’s mid-caps have returned -3.8%, IBB has returned -2.9%, and SPY has returned -0.1%.

Kite Pharma presents Phase 1 results from Zuma-1

Kite Pharma rose by 1.2% on positive data from its Phase 1 clinical trial of Zuma-1. As per its press release, KITE announced “clinical biomarker data and product characteristics for anti-CD19 chimeric antigen receptor (or CAR) T-cell therapy in patients with relapsed/refractory non-Hodgkin lymphoma (or NHL) enrolled in an ongoing phase 1-2 clinical trial at the National Cancer Institute (or NCI), which is being conducted under a Cooperative Research and Development Agreement (or CRADA) between Kite and the NCI. In this clinical trial, patients with a range of B cell cancers were conditioned with cyclophosphamide and fludarabine prior to receiving anti-CD19 CAR T cell therapy.”

The results were announced at the 57th American Society of Hematology annual meeting in Orlando, Florida.

KITE closed at $71.26 on December 7, 2015, and was trading above its 100-day moving average but below its 20-day moving average. KITE has a book value of $8.24 per share. With its current price, the stock is being traded at a price-to-book value of 8.65x. KITE has a weight of ~0.6% in IBB’s portfolio.

Continue to Next Part

Browse this series on Market Realist: